Press Releases (Archive)

2010 Press Releases
2009 Press Releases
2008 Press Releases
2007 Press Releases
2006 Press Releases
2005 Press Releases
2004 Press Releases
2003 Press Releases
2002 Press Releases

Click PDF to download an Acrobat PDF file for printing or distribution.

2010
Laureate Pharma Announces New Development and Manufacturing Agreement To Produce AVEO Pharmaceuticals’ Antibody Therapeutic 10/27/2010 PDF
Laureate Pharma Secures $20 Million to Enhance and Grow Biopharmaceutical Contract Manufacturing Business 10/6/2010 PDF
Laureate Pharma and Iconic Therapeutics Announce Production of Clinical Material 1/7/2010 PDF
Laureate Pharma and Selexis Announce Collaboration 1/5/2010 PDF
Back To Top
2009
Laureate Pharma Welcomes Three New Members to Business Development Team 11/2/2009 PDF
LAUREATE PHARMA ANNOUNCES SIGNING NEW BIOPHARMACEUTICAL DEVELOPMENT & MANUFACTURING AGREEMENT 10/21/2009 PDF
LAUREATE PHARMA ANNOUNCES DEVELOPMENT & MANUFACTURING AGREEMENT WITH ZZ BIOTECH 9/24/2009 PDF
LAUREATE PHARMA AND NEOPROBE CORPORATION ANNOUNCE MANUFACTURING ALLIANCE 9/8/2009 PDF
Laureate Pharma Elects New Board Member 8/18/2009 PDF
Laureate Pharma Appoints Daniel E. Leone as Vice President of Business Development 7/27/2009 PDF
Back To Top
2008
Laureate Pharma Honored as Emerging Life Sciences Company of the Year 11/20/2008 PDF
Laureate Pharma Announces Agreement With Tolera Therapeutics, Inc. 10/28/2008 PDF
Laureate Announces Manufacturing Agreement with Tolerx 10/21/2008 PDF
Laureate Pharma To Add More Manufacturing Capacity 9/18/2008 PDF
Laureate Pharma Announces Manufacturing Agreement with Alopexx Pharmaceuticals, LLC. 4/10/2008 PDF
Laureate Pharma Reports Record Growth for 2007 4/1/2008 PDF
Laureate Announces Second Manufacturing Agreement with Cytheris 3/27/2008 PDF
Laureate Pharma Appoints Gary Swan as Vice President of Operations 2/14/2008 PDF
Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody 1/31/2008 PDF
Back To Top
2007
Laureate Pharma Reports Consecutive Quarter of Record-Breaking Performance 11/7/2007 PDF
Laureate Pharma Announces Agreement with ImmunoGen 11/1/2007 PDF
Laureate Pharma Recognizes 178% Revenue Growth Year-over-Year 8/7/2007 PDF
Laureate Pharma Announces Agreement with Enobia Pharma, Inc. 7/31/2007 PDF
Laureate Pharma’s Momentum Continues in First Quarter 2007 5/3/2007 PDF
Laureate Pharma Extends Lease for its Facility in Princeton, NJ 4/25/2007 PDF
Laureate Pharma Announces Grand Opening of its Pilot Plant in Princeton, NJ 3/28/2007 PDF
Laureate Pharma Elects New Chairman 2/28/2007 PDF
Laureate Pharma Announces Collaboration with Boehringer Ingelheim 2/6/2007 PDF
Laureate Pharma Reports Record Growth in 2006 1/31/2007 PDF
Laureate Pharma Announces Agreement with Trubion Pharmaceuticals 1/30/2007 PDF
Back To Top
2006
Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT ® 10/25/2006 PDF
Laureate Pharma to Produce Lpath’s Breakthrough Therapeutic Antibody for Phase I Clinical Trials 8/22/2006 PDF
Laureate Pharma Announces $9 Million Expansion of Manufacturing Facility in Princeton 6/8/2006 PDF
Laureate Pharma To Sponsor Free Webcast On Development Of Radiolabeled Antibodies To Treat Prostate Cancer 6/1/2006 PDF
Laureate Pharma and Iconic Therapeutics, Inc. Announce Immunoprotein Manufacturing Agreement 5/10/2006 PDF
Laureate Pharma and Seattle Genetics Announce Manufacturing Agreement 4/25/2006 PDF
Laureate Pharma and Bradmer Pharmaceuticals Announce Development of Brain Cancer Treatment Product 3/16/2006 PDF
Laureate Pharma Completes Sale of Totowa, NJ Operations to Discovery Laboratories for $16.0 Million 1/3/2006 PDF
Back To Top
2005
Laureate Pharma Inc. Enters into Agreement to Sell its Totowa, NJ Operations to Discovery Laboratories for $16 Million 12/28/2005 PDF
Laureate Pharma and Enobia Pharma Announce Development and Manufacturing Agreement on Therapeutic Enzyme Product 9/21/2005 PDF
Michael Cavanaugh Joins Laureate Pharma To Lead Sales, Marketing and Business Development Activities 9/7/2005 PDF
Laureate Pharma, Inc. and EMD Chemicals Inc. Team Up For Strategic Collaboration 3/3/2005 PDF
Laureate Pharma Sees Bright Future As Newest Safeguard Scientifics Company 1/7/2005 PDF
Back To Top
2004
Safeguard Scientifics Completes Acquisition of Laureate Pharma 12/6/2004 PDF
Laureate Pharma L.P. Announces Operation of 2500 Liter Bioreactor 6/3/2004 PDF
Laureate Pharma L.P. and GTC Biotherapeutics enter strategic collaboration 3/9/2004 PDF
Laureate Pharma L.P. announces technology transfer and manufacturing agreement with Discovery Laboratories, INC. 1/21/2004 PDF
Back To Top
2003
Laureate Pharma and FeRx Announce Manufacturing Service Agreement 10/14/2003 PDF
Laureate Pharma Expands Protein-Purification Capacity 6/17/2003 PDF
Laureate Pharma L.P. Announces Operation of New Bioreactor 5/14/2003 PDF
Laureate Pharma L.P. and TolerRx, Inc. Announce Second Antibody Manufacturing Services Agreement 3/26/2003 PDF
Laureate Pharma L.P. Announces the Election of Lawrence W. Chakrin to its Board of Directors 1/7/2003 PDF
Back To Top
2002
Stan Zeichner Named Director, Sales & Marketing at Laureate Pharma L.P. 12/5/2002 PDF
John J. Morris Named Vice President, Controller & Strategic Planning at Laureate Pharma L.P. 11/4/2002 PDF
Laureate Pharma L.P. Announces the Election of F. Peter Boer to its Board of Directors 10/17/2002 PDF
Laureate Pharma L.P. and Southern Research Institute announce drug delivery and commercial manufacturing strategic collaboration agreement 9/10/2002 PDF
Laureate Pharma L.P. and TolerRx, Inc. Announce Antibody Manufacturing Services Agreement 8/20/2002 PDF
Laureate Pharma and DrugAbuse Sciences Announce Commercial Manufacturing Services Agreement 6/24/2002 PDF
Laureate Pharma Launches New Contract Manufacturing Venture 5/21/2002 PDF
PDF

Pharmacy News

Laureate and ARIUS Cooperation

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating…

Laureate Announces Second Manufacturing Agreement with Cytheris

Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for…

Laureate Pharma Agreement with Alopexx Pharmaceuticals

Laureate To Manufacture Alopexx’s Product Candidate On April 10, 2008, Laureate Pharma, Inc., a large company engaged in biopharmaceutical development and protein production reported that it has concluded a contract manufacturing agreement with Alopexx Pharmaceuticals on the production of Alopexx’s mAb F598 antibody under cGMP conditions. This antibody will be used in clinical trials and also for fighting Staphylococcus aureus infections. The details of the agreement were not announced. “We are happy that Laureate…

Laureate Pharma Company – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma Launches New Contract Manufacturing Venture Company offers services for development and manufacture of biopharmaceuticals and sustained-release products Princeton, NJ – May 21, 2002 – Laureate Pharma Company announces the launch of contract manufacturing services at its two sites in New Jersey. Biopharmaceutical development and manufacturing services will be provided at a cGMP manufacturing facility in Princeton, NJ. Services related to sustained release microsphere products will…

Laureate Pharma Extends its Agreement with Cytogen for Manufacture of PROSTASCINT®

Princeton, NJ – October 25, 2006: Laureate Pharma, Inc. announced today that it has renewed its agreement with Cytogen Corporation for the cGMP manufacture of ProstaScint®, Cytogen’s proprietary monoclonal antibody immunoconjugate that is used for imaging in patients diagnosed with prostate cancer. Under the agreement, Laureate will provide cGMP protein production, purification, conjugation of Cytogen’s proprietary linker chelator and aseptic filling services to support Cytogen’s commercial ProstaScint® requirements. Terms of…

Laureate Pharma & DrugAbuse Sciences – Press Release

FOR IMMEDIATE RELEASE Laureate Pharma and DrugAbuse Sciences Announce Commercial Manufacturing Services Agreement. Princeton, NJ – June 24, 2002 – Laureate Pharma L.P. and DrugAbuse Sciences, Inc. announce the initiation of a contract manufacturing agreement related to a sustained release microsphere product. Under the agreement, Laureate Pharma will provide manufacturing services for DrugAbuse Sciences’ Naltrexone Depot product, currently in clinical trials. Terms of the agreement were not disclosed. “We are…

LAUREATE PHARMA COMPLETES SALE OF TOTOWA, NJ OPERATIONS TO DISCOVERY LABORATORIES FOR $16.0 MILLION

Laureate’s Bioprocessing Facility at Princeton, NJ to be Expanded Princeton, NJ – January 3, 2006 – Laureate Pharma, Inc., a wholly-owned subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE), announced today that it had completed the previously announced sale of its Totowa, NJ operations to Discovery Laboratories, Inc. (NASDAQ: DSCO) for $16.0 million in cash. Laureate Pharma, a provider of bioprocessing services to pharmaceutical and biopharmaceutical companies, conducts its principal operations…

Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality

– Leads implementation of Laureate’s strategic quality plan – PRINCETON, N.J., March 16, 2011 — Laureate Biopharmaceutical Services, Inc., a full-service biopharmaceutical contract development and manufacturing organization, today announced the appointment of Ann M. Daus, Ph.D, as Vice President, Quality. Dr. Daus will lead the implementation of Laureate’s strategic quality plan, recruit new leaders to supplement the quality management team, lead the strategic expansion of testing services and improve companywide…

Laureate Pharma Honored as Emerging Life Sciences Company of the Year

Laureate recognized for its business growth, leadership team and service innovation by the Eastern Technology Council Princeton, NJ, November 20, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has been named the “Emerging Life Science Company of the Year” by The Eastern Technology Council, the largest technology and life sciences trade association in the greater Philadelphia, PA region. The company was honored…

Laureate Pharma Announces Manufacturing Agreement with Alopexx Pharmaceuticals, LLC

Laureate To Manufacture Alopexx’s Product Candidate Princeton, NJ, April 10, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the agreement, Laureate will produce Alopexx’s mAb F598 antibody under cGMP conditions. This antibody is planned for use in clinical trials, and later for commercial production for the treatment and…

Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody

Laureate to Manufacture ARIUS’ Product Candidate Trop-2 Signal Transduction Antibody Princeton, NJ, January 31, 2008: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced that it has entered into a cGMP contract manufacturing agreement with ARIUS Research, Inc., a biotechnology company focused on discovering and developing the next wave of antibody therapeutics to treat cancer and other diseases, for its Trop-2 Signal Transduction Antibody Program. Laureate…

LAUREATE PHARMA ANNOUNCES AGREEMENT WITH TRUBION PHARMACEUTICALS

LAUREATE TO MANUFACTURE TRUBION’S TRU-016 PRODUCT CANDIDATE Princeton, NJ, January 30, 2007: Laureate Pharma, Inc., a full-service biopharmaceutical development and protein production company, today announced it has entered into an agreement to produce Trubion Pharmaceuticals, Inc.’s TRU-016, a novel protein for the treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukemia (CLL). Terms of the manufacturing agreement were not disclosed. Trubion’s TRU-016 program targets CD37, an antigen present on B…